Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Efficacy and safety of an 8-week bemnifosbuvir and ruzasvir regimen in chronic hepatitis C: Results from a Phase 2 study.

BACKGROUND AIMS Bemnifosbuvir and ruzasvir are potent pan-genotypic inhibitors of the hepatitis C virus (HCV) NS5B polymerase and NS5A protein, respectively. This single-arm, Phase 2 study evaluated the efficacy and safety of bemnifosbuvir and ruzasvir in treatment-naïve patients with chronic HCV infection of any genot...

A. Jucov, Brian Conway, J. Feld et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.